Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of Short-Term Use of N-Acetylcysteine as a Strategy for Prevention of Anthracycline-Induced Cardiomyopathy: EPOCH Trial - A Prospective Randomized Study

  • Jo, Sang-Ho (Division of Cardiology, Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Kim, Lee Su (Division of Breast and Endocrine Surgery, Hallym University Sacred Heart Hospital) ;
  • Kim, Sung-Ai (Division of Cardiology, Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Kim, Hyun-Sook (Division of Cardiology, Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Han, Sang-Jin (Division of Cardiology, Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Park, Woo Jung (Division of Cardiology, Department of Internal Medicine, Hallym University Sacred Heart Hospital) ;
  • Choi, Young Jin (Division of Cardiology, Department of Internal Medicine, Sejong General Hospital)
  • Published : 2013.03.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: We investigate to determine whether N-acetylcysteine (NAC) can prevent anthracycline-induced cardiotoxicity. Subjects and Methods: A total of 103 patients were enrolled in this prospective randomized open label controlled trial. They are patients first diagnosed with breast cancer or lymphoma, who require chemotherapy, including anthracycline like adriamycine or epirubicine. Patients were randomized to the NAC group {n=50; 1200 mg orally every 8 hours starting before and ending after the intravenous infusion of anthracycline in all chemotherapy cycles (3-6)} or the control group (n=53). Primary outcome was the decrease in left ventricular ejection fraction (LVEF) absolutely ${\geq}10%$ from the baseline and concomitantly <50% at 6-month. Composite of all-cause death, heart failure and readmission were compared. Results: The primary outcome was not significantly different in the NAC and control groups {3/47 (6.4%) vs. 1/52 (1.9%), p=0.343}. The mean LVEF significantly decreased in both the NAC (from 64.5 to 60.8%, p=0.001) and control groups (from 64.1 to 61.3%, p<0.001) after the completion of whole chemotherapy. The mean LVEF change did not differ between the two groups (-3.64% in NAC vs. -2.78% in control group, p=0.502). Left ventricular (LV) end systolic dimension increased with higher trend in NAC by $3.08{\pm}4.56 mm$ as compared with $1.47{\pm}1.83mm$ in the control group (p=0.064). LV end diastolic dimension did not change in each group and change does not differ in both. Peak E, A and E/A ratio change and cardiac enzymes were comparable in two groups. Cumulative 12-month event rate was 6% and 3.8% in the NAC group and the control group, respectively, with no difference (p=0.672). Conclusion: We cannot prove that NAC prevents anthracycline-induced cardiomyopathy.

Keywords

References

  1. Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004;22:1864-71. https://doi.org/10.1200/JCO.2004.06.033
  2. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749-54. https://doi.org/10.1161/01.CIR.0000130926.51766.CC
  3. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978;62:873-9.
  4. Zucchi R, Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anticancer Agents 2003;3:151-71. https://doi.org/10.2174/1568011033353434
  5. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007;49:330-52. https://doi.org/10.1016/j.pcad.2006.10.002
  6. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109:3122-31. https://doi.org/10.1161/01.CIR.0000133187.74800.B9
  7. Deng S, Kruger A, Kleschyov AL, Kalinowski L, Daiber A, Wojnowski L. Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. Free Radic Biol Med 2007;42:466-73. https://doi.org/10.1016/j.freeradbiomed.2006.11.013
  8. Spallarossa P, Altieri P, Garibaldi S, et al. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 2006;69:736-45. https://doi.org/10.1016/j.cardiores.2005.08.009
  9. Doroshow JH, Locker GY, Ifrim I, Myers CE. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest 1981; 68:1053-64. https://doi.org/10.1172/JCI110328
  10. Rosenthal DS, Braunwald E. Cardiac effects of radiation therapy and chemotherapy. In: Braunwald E editor. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: WB Saunders Co.;2001. p.1746-51.
  11. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263-302. https://doi.org/10.2165/00002018-200022040-00002
  12. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy- induced cardiotoxicity in high-risk patients by angiotensin- converting enzyme inhibition. Circulation 2006;114:2474-81. https://doi.org/10.1161/CIRCULATIONAHA.106.635144
  13. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43. https://doi.org/10.1056/NEJM199506293322602
  14. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7. https://doi.org/10.1001/jama.1991.03470120074036
  15. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-79. https://doi.org/10.1002/cncr.11407
  16. Figueredo VM. Chemical cardiomyopathies: the negative effects of medications and nonprescribed drugs on the heart. Am J Med 2011;124:480-8. https://doi.org/10.1016/j.amjmed.2010.11.031
  17. Hong HJ, Liu JC, Chen PY, Chen JJ, Chan P, Cheng TH. Tanshinone IIA prevents doxorubicin-induced cardiomyocyte apoptosis through Aktdependent pathway. Int J Cardiol 2012;157:174-9. https://doi.org/10.1016/j.ijcard.2010.12.012
  18. Chao HH, Liu JC, Hong HJ, Lin JW, Chen CH, Cheng TH. L-carnitine reduces doxorubicin-induced apoptosis through a prostacyclin-mediated pathway in neonatal rat cardiomyocytes. Int J Cardiol 2011;146:145-52. https://doi.org/10.1016/j.ijcard.2009.06.010
  19. Li L, Takemura G, Li Y, et al. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 2006;113:535-43. https://doi.org/10.1161/CIRCULATIONAHA.105.568402
  20. Li K, Sung RY, Huang WZ, et al. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006;113:2211-20. https://doi.org/10.1161/CIRCULATIONAHA.105.560250
  21. Neilan TG, Jassal DS, Scully MF, et al. Iloprost attenuates doxorubicininduced cardiac injury in a murine model without compromising tumour suppression. Eur Heart J 2006;27:1251-6. https://doi.org/10.1093/eurheartj/ehl003
  22. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-62. https://doi.org/10.1016/j.jacc.2006.07.052
  23. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4. https://doi.org/10.1056/NEJM200007203430304
  24. Feola M, Garrone O, Occelli M, et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 2011;148:194-8. https://doi.org/10.1016/j.ijcard.2009.09.564
  25. Lee CY, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev 2007;12:131-42. https://doi.org/10.1007/s10741-007-9016-3
  26. Urbanova D, Urban L, Danova K, Simkova I. Natriuretic peptides: biochemical markers of anthracycline cardiac toxicity? Oncol Res 2008;17:51-8. https://doi.org/10.3727/096504008784523621
  27. Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011;57:2263-70. https://doi.org/10.1016/j.jacc.2010.11.063

Cited by

  1. Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy vol.76, pp.6, 2013, https://doi.org/10.1007/s00280-015-2879-4
  2. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment : Integrative Therapies During and After Breast Cancer Treatment vol.67, pp.3, 2013, https://doi.org/10.3322/caac.21397
  3. Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring vol.96, pp.2, 2013, https://doi.org/10.1124/mol.119.115725
  4. Doxorubicin-Induced Ascension of Resident Cardiac Macrophages vol.127, pp.5, 2013, https://doi.org/10.1161/circresaha.120.317626
  5. Preventing and Treating Anthracycline Cardiotoxicity: New Insights vol.61, pp.1, 2013, https://doi.org/10.1146/annurev-pharmtox-030620-104842